Business Wire

ETH Zurich, INSAIT, and LatticeFlow AI Launch the First EU AI Act Compliance Evaluation Framework for Generative AI

Share

ETH Zurich, INSAIT, and LatticeFlow AI announce the release of the first evaluation framework of the EU AI Act for Generative AI models.

The release, available at https://compl-ai.org, includes the first technical interpretation of the EU AI Act, mapping regulatory requirements to technical ones, together with a free and open-source framework to evaluate Large Language Models (LLMs) under this mapping. The launch also features the first compliance-centered evaluation of public foundation models from organizations such as OpenAI, Meta, Google, Anthropic, and Alibaba against the EU AI Act technical interpretation.

Thomas Regnier, the European Commission's spokesperson for digital economy, research, and innovation, commented on the release: ​“The European Commission welcomes this study and AI model evaluation platform as a first step in translating the EU AI Act into technical requirements, helping AI model providers implement the AI Act.”

First Technical Interpretation of the EU AI Act

The EU AI Act outlines high-level regulatory requirements without providing detailed technical guidelines. To address this, the European Commission has launched a consultation on the Code of Practice for providers of general-purpose Artificial Intelligence (GPAI) models, tasked to supervise the implementation and enforcement of the AI Act rules on GPAI. COMPL-AI can also benefit the GPAI working groups, which can use it as a starting point for their efforts.

COMPL-AI includes also a free and open-source framework built upon 27 state-of-the-art benchmarks that can be used to evaluate LLMs against these technical requirements.

We invite AI researchers, developers, and regulators to join us in advancing this evolving project,said Prof. Martin Vechev, Full Professor at ETH Zurich and Founder and Scientific Director of INSAIT in Sofia, Bulgaria.We encourage other research groups and practitioners to contribute by refining the AI Act mapping, adding new benchmarks, and expanding this open-source framework. The methodology can also be extended to evaluate AI models against future regulatory acts beyond the EU AI Act, making it a valuable tool for organizations working across different jurisdictions.

With this framework, any company can now evaluate their AI systems against the EU AI Act technical interpretation. Our vision is to enable organizations to ensure that their AI systems are not only high-performing but also fully aligned with the regulatory requirements, said Dr. Petar Tsankov, CEO and Co-Founder at LatticeFlow AI.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241016758271/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Visa and Analytic Partners Announce Multi-Year Deal to Transform Commercial Analytics for Merchants and Brands16.10.2024 14:00:00 CEST | Press release

Exclusive global partnership to empower businesses to find new growth through advanced analytics solutions for marketing and brand spend optimization Visa (NYSE: V), a global leader in digital payments, today announced that it has entered into a new strategic partnership with Analytic Partners, a global analytics solution provider. Together, Visa and Analytic Partners plan to address commercial challenges faced by merchants and brands, including improving the return on advertising investments, with value-enhancing AI-driven data analytics. In a dynamic business environment rich with data, companies need meaningful, near-real-time insights to make informed decisions, yet solutions are often fragmented or not actionable. The partnership will combine Visa’s merchant relationships and consumer spend insights with Analytic Partners’ commercial decisioning platform to bring powerful marketing spend optimization analytics to merchants and brands around the world. “The volume of data available

Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy16.10.2024 14:00:00 CEST | Press release

− Type II Variation Submission Based on the Positive HELIOS-B Phase 3 Study in which Vutrisiran Significantly Reduced the Risk of Death and Cardiovascular Events Relative to Placebo – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced the submission of a Type II Variation to the European Medicines Agency (EMA) for vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Vutrisiran is the generic name for AMVUTTRA®, which is currently approved in the European Union (EU) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy. “Today marks another important milestone in our journey to bring RNAi therapeutics to patients with high unmet need around the world,” said Pushkal Garg, M.D., Chief Medical Officer of Alnylam. “ATTR-CM is a rapidly progressive, debilitating, and li

Interactive Brokers Opens New Office in DIFC Dubai16.10.2024 14:00:00 CEST | Press release

Investors in the UAE and GCC Benefit from IBKR’s Global Trading Expertise Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the opening of a new office in Dubai International Financial Center (DIFC). Through this new office, Interactive Brokers will establish its presence in the Middle East, complementing its existing strategy of providing global clients with a cost-effective brokerage service that easily facilitates access to global markets trading. Active traders, high-net-worth investors, and a range of wealth management institutions, including local banks, hedge funds and family offices in the region, can take advantage of Interactive Brokers’ powerful trading technology and tools, competitive pricing, and a broad selection of investment products. The financial services industry continues to grow in the UAE and throughout the GCC region as more individuals seek to engage with financial markets actively. With over three million clients in ove

NEQSOL Holding Acquires One of the World’s Largest Titanium Producers16.10.2024 13:53:00 CEST | Press release

NEQSOL Holding, a global investment group managing diverse businesses across 11 countries from headquarters in Amsterdam, Baku, and Kyiv, is currently in the process of acquiring the United Mining and Chemical Company JSC (UMCC) – one of the largest titanium ore raw material producers in the world. Cemin Ukraine, a company part of NEQSOL Holding, is in the process of purchasing 100% of the shares of the state-owned United Mining and Chemical Company following an auction for the company’s privatization. The privatization deal was approved by the Cabinet of Ministers of Ukraine and is now subject to further regulatory approval. United Mining and Chemical Company JSC is among the top ten producers and processors of titanium and zirconium ore concentrates in the world. In 2020, the company recorded production of 350,000 tons of titanium and zirconium ore concentrates. UMCC was established by the government of Ukraine to manage and operate Vilnohirsk Mining and Metallurgical Plant in the Dn

Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration16.10.2024 13:00:00 CEST | Press release

Both programmes demonstrate Exscientia’s ability to design highly differentiated, potentially best-in-class moleculesExscientia will receive $15 million for achieving these milestones and is eligible for over $600 million in additional milestone payments for these two programmes as well as high-single-digit to mid-teen royaltiesThree programmes in the partnership have now advanced through initial milestones with multiple more progressing at earlier stages Exscientia plc (Nasdaq: EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds have met the product profile requirements, set by both Exscientia and Sanofi, to enable a transition to the lead optimisation phase within the collaboration. Both programmes have also shown a high level of differentiation in early profiling and have the potential to produce best-in-class assets. “We are

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye